1800-272-662
Shopping Cart 0
countryflagAU
Login

ReShape Lifesciences Inc

Healthcare US RSLS

NoneUSD
-(-%)

Last update at 2025-08-28T20:12:08.189619Z

Day Range

--
LowHigh

52 Week Range

0.142.58
LowHigh

Fundamentals

  • Previous Close 15.68
  • Market Cap4.87M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-11.10600M
  • Revenue TTM8.34M
  • Revenue Per Share TTM0.73
  • Gross Profit TTM 6.80M
  • Diluted EPS TTM-0.44

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -46.59400M -62.03900M -21.81100M -75.10000M -38.71373M
Minority interest - - - - -
Net income -46.21400M -61.93300M -21.63000M -74.20700M -81.15157M
Selling general administrative 17.25M 24.41M 10.53M 17.22M 19.26M
Selling and marketing expenses 14.09M 9.16M 4.69M 4.85M -
Gross profit 6.80M 8.35M 6.26M 9.30M 0.44M
Reconciled depreciation 2.15M 1.97M 1.67M 1.71M 0.44M
Ebit -27.07800M -29.72000M -14.12400M -15.88700M -24.55203M
Ebitda -24.91400M -27.74900M -12.45700M -17.22400M -24.11147M
Depreciation and amortization 2.16M 1.97M 1.67M -1.33700M 0.44M
Non operating income net other - - -7.30500M -1.16100M -0.15539M
Operating income -27.07800M -27.74900M -12.45700M -15.88700M -38.54596M
Other operating expenses 38.32M 41.35M 23.76M 30.98M 25.15M
Interest expense 0.11M 0.83M 2.05M 0.45M 0.01M
Tax provision -0.38000M -0.10600M -0.18100M -0.89300M -3.44671M
Interest income - - - - -
Net interest income -0.11300M -0.83200M -2.04900M -0.45100M -0.01238M
Extraordinary items - - - - -
Non recurring - - - 8.09M 14.00M
Other items - - - - -
Income tax expense -0.38000M -0.10600M -0.18100M -0.89300M -3.44671M
Total revenue 11.24M 13.60M 11.30M 15.09M 0.61M
Total operating expenses 33.88M 36.10M 18.72M 25.19M 24.98M
Cost of revenue 4.44M 5.25M 5.04M 5.78M 0.16M
Total other income expense net -19.51600M -34.29000M -9.35400M -59.21300M -14.15997M
Discontinued operations - - - - -45.88500M
Net income from continuing ops -46.21400M -61.93300M -21.63000M -74.20700M -35.26702M
Net income applicable to common shares -46.21400M -61.93300M -21.63000M -74.20700M -84.23056M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 10.73M 11.14M 54.26M 37.06M 39.66M
Intangible assets - 0.26M 20.83M 27.02M 28.67M
Earning assets - - - - -
Other current assets 0.34M 0.08M 1.62M 1.07M 1.71M
Total liab 4.06M 7.48M 8.19M 22.57M 15.55M
Total stockholder equity 6.66M 3.66M 46.07M 14.49M 24.11M
Deferred long term liab - - - 0.61M 0.70M
Other current liab 1.34M 4.87M 3.04M 7.24M 5.63M
Common stock 0.02M 0.00100M 0.02M 0.00600M 0.00800M
Capital stock 0.02M 0.00100M 0.02M 0.00700M 0.00100M
Retained earnings -635.57400M -624.18700M -576.76000M -514.82700M -493.19700M
Other liab - - 0.85M 1.64M 4.68M
Good will - - - - -
Other assets - 0.10M 1.46M 0.05M 0.10M
Cash 4.56M 3.85M 22.77M 2.96M 2.94M
Cash and equivalents - - - - -
Total current liabilities 3.78M 7.48M 7.33M 11.61M 10.39M
Current deferred revenue 0.64M 0.51M 0.55M 0.40M 0.20M
Net debt -4.29700M -3.68400M -22.48600M -2.48000M -2.16700M
Short term debt 0.11M 0.17M 0.28M 0.31M 0.29M
Short long term debt - - - - -
Short long term debt total 0.26M 0.17M 0.28M 0.48M 0.77M
Other stockholder equity 642.30M 627.93M 622.91M 529.43M 517.30M
Property plant equipment - 0.87M 1.72M 0.58M 0.02M
Total current assets 10.30M 9.91M 30.25M 8.94M 10.11M
Long term investments - - - - -
Net tangible assets - 3.40M 25.25M -12.53500M -4.56800M
Short term investments - - - - -
Net receivables 1.66M 2.18M 2.81M 2.62M 4.10M
Long term debt - - - 9.17M 2.73M
Inventory 3.74M 3.61M 3.00M 2.24M 1.32M
Accounts payable 1.69M 1.93M 3.47M 3.65M 4.26M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.08800M -0.08800M -0.09200M -0.12100M -0.00800M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00600M -
Preferred stock total equity - - - 0.00100M 0.00100M
Retained earnings total equity - - - -514.82700M -493.19700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M 0.05M 1.46M 0.05M 0.10M
Deferred long term asset charges - - - - -
Non current assets total 0.43M 1.23M 24.00M 28.12M 29.55M
Capital lease obligations 0.26M 0.17M 0.28M 0.48M 0.77M
Long term debt total - - - 9.17M 2.73M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.08900M -0.09200M 1.85M -2.39000M -2.01400M
Change to liabilities - 0.45M -1.48000M -0.99200M 1.63M
Total cashflows from investing activities - -0.09200M 1.85M -2.39000M -2.01400M
Net borrowings - - -9.50000M 10.40M -0.22100M
Total cash from financing activities 17.57M 3.13M 33.30M 11.07M 13.66M
Change to operating activities - 0.77M -0.60800M 0.96M 0.89M
Net income -11.38700M -46.21400M -61.93300M -21.63000M -74.20700M
Change in cash 0.60M -18.86000M 19.81M 0.02M -2.56300M
Begin period cash flow 3.96M 22.82M 3.01M 2.98M 5.55M
End period cash flow 4.56M 3.96M 22.82M 3.01M 2.98M
Total cash from operating activities -16.96000M -21.90200M -15.37500M -8.55000M -14.20000M
Issuance of capital stock - 0.64M 0.00000M -14.60500M 0.48M
Depreciation 0.15M 2.15M 1.97M 1.67M 1.71M
Other cashflows from investing activities - - - -2.00000M -2.00000M
Dividends paid - - - - -
Change to inventory -0.46500M -1.18700M -0.36900M -1.17500M -0.33200M
Change to account receivables 0.12M 0.68M -0.28400M 0.28M 0.58M
Sale purchase of stock - - - 0.68M 13.40M
Other cashflows from financing activities 17.57M 2.49M 40.99M 20.79M 13.66M
Change to netincome - 21.45M 46.83M 9.46M 57.84M
Capital expenditures 0.04M 0.13M 0.35M 0.39M 0.01M
Change receivables - - - 1.22M -3.61900M
Cash flows other operating - - - 1.20M 2.34M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 0.14M -2.55500M
Change in working capital -4.13400M 0.71M -2.74100M 0.00600M -1.42800M
Stock based compensation 0.77M 2.09M 12.23M 1.32M 2.31M
Other non cash items -2.38700M 19.79M 34.64M 10.17M 58.56M
Free cash flow -17.00300M -22.03300M -15.72700M -8.94000M -14.21400M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RSLS
ReShape Lifesciences Inc		 - -% - - - 0.45 0.58 0.28 0.02
ABT
Abbott Laboratories		 -0.27 0.24% 110.28 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -14.43 4.02% 344.22 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.83 0.92% 89.06 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.52 2.17% 68.44 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

ReShape Lifesciences Inc

1001 Calle Amanecer, San Clemente, CA, United States, 92673

Key Executives

Name Title Year Born
Mr. Dan W. Gladney Exec. Chair 1953
Mr. Thomas Stankovich Sr. VP of Fin. & CFO 1961
Mr. Paul F. Hickey CEO, Pres & Director 1965
Dr. Mark B. Knudson Ph.D. Co-Founder and Special Advisor to the CEO 1949
Dr. Katherine S. Tweden Ph.D. Co-Founder 1961
Mr. Al Diaz VP of Operations and R&D NA
Dr. Dov Gal D.V.M., DVM, M.B.A., MBA VP of Regulatory Clinical Quality & Compliance Officer NA
Jody B. Dahlman Director of Communications NA
Mr. Naqeeb A. Ansari Sr. VP of Global Commercial Operations 1961
Mr. Dan W. Gladney Executive Chair 1953

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.